Volume 5, Issue 12: Non-pulmonary CFTR modification targets
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 5, Issue 12)
Target Audience
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
Learning Objectives
After participating in this activity, the participant will demonstrate the ability to:
- Describe the effects of CFTR modulation on nutritional status
- Evaluate the observational data supporting the impact of CFTR modulation on chronic infection in CF
- Summarize the newer advances in our understanding of the pathophysiology of CF and how CFTR modulation may impact this process
Christopher Goss, MD
Professor
Division of Pulmonary and Critical Care Medicine
Professor of Pediatrics
University of Washington Medical Center
Seattle, Washington
Disclosure
Dr. Christopher Goss reports that he has research grant funding from Vertex Pharmaceuticals Inc. In addition, he has received honoraria from Gilead Sciences and L. Hoffman–La Roche Ltd.
Unlabeled/Unapproved Uses
Dr. Christopher Goss has reports that the activity will not contain any discussion of off-label or unapproved drugs or products, with the exception of ataluren
Available Credit
- 0.50 ANCC
- 0.50 Attendance